CD226 and neoplasm: Emerging preclinical evidence positions CD226 activation as a pivotal amplifier of anti-tumor immunity, synergizing with chemotherapy, immune checkpoint blockade, and vaccine strategies to enhance NK/cytotoxic T lymphocyte (CTL) cytotoxicity across diverse malignancies.